Article
Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2020
Bachet Jean-Baptiste, Blons Hélène, Hammel Pascal, Hariry Iman El, Portales Fabienne, Mineur Laurent, Metges Jean-Philippe, Mulot Claire, Bourreau Camille, Cain Jason, Cros Jérôme, Laurent-Puig Pierre
Abstract excerpt
PURPOSE: Eryaspase is composed of l-asparaginase encapsulated in erythrocytes and has demonstrated significant efficacy in a randomized phase II trial. We assessed the prognostic and predictive value of circulating tumor DNA (ctDNA) in patients, plasma included in this trial. EXPERIMENTAL DESIGN: Samples prospectively collected pretreatment were centrally analyzed by next-generation sequencing. Prognostic values...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.